Agenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer - AGEN News | RalliesAgenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer
A
AGEN• Investor deck highlights Phase 3 neoadjuvant trial
- Agenus outlined a registrational Phase 3 “ROBBIN” trial of botensilimab with balstilimab in neoadjuvant MSS colon cancer.
- Trial design: n=850, randomized 1:1, primary endpoint event-free survival; first patient in projected by Q1 2027.
- Across NEST and UNICORN investigator studies, 38 MSS colon patients showed about 30% pCR, about 40% MPR, 100% EFS at 9-18 months.
- Tolerability in neoadjuvant studies: low Grade ≥3 adverse events; one surgery delay of 10 days among 52 treated patients.
- July PIPE financing expected to fund ROBBIN trial costs, operations through end-2031, assuming full warrant exercise.
•
